Project Grant R01HL173239
Award Date
4/1/25
Completion Date
1/31/30
Dollars Obligated
$760K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
This Project Grant award in the amount of $127,875 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant will fund multi-omic characterization of immune cells in sarcoidosis, a systemic granulomatous disease, at the Oklahoma Medical Research Foundation (OMRF). The key objectives are to: 1) develop predictive models of sarcoidosis susceptibility and disease burden using circulating protein levels, and...
The federal Project Grant award R01HL174432, in the amount of $751,954, was issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award, effective August 1, 2024 through April 30, 2029, will support research at Stanford University to investigate the use of CXCR3 blockade as a potential precision therapy for cardiac sarcoidosis.
The research project aims to utilize single-cell multi-omics and T-cell receptor...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research aimed at determining the role of specialized pro-resolving mediators (SPMs) in resolving inflammation and improving respiratory outcomes in individuals with emphysema. The award, totaling $139,088, will be used to characterize circulating SPM concentrations as a biomarker for decreased potential to resolve chronic...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $200,502 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The Regents of the University of California, San Francisco (UCSF) to support research on proteomic and metabolomic trajectories of acute respiratory distress syndrome (ARDS) molecular phenotypes. The funding will allow the principal investigator, Dr. Narges Alipanah-Lechner, to develop expertise in computational methods, epidemiologic approaches, and systems...
This $374,063 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research to better understand the mechanisms regulating granuloma formation and fibrosis in sarcoidosis. The key products and services to be delivered under this 2-year award include:
Determining if activation of the renin-angiotensin-aldosterone system (RAAS) and mineralocorticoid receptors (MRs) promotes sarcoidosis...
This $503,496 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to improve treatment and outcomes for patients with hospital-onset sepsis at risk of acute respiratory failure (ARF). The key objectives are to: 1) Identify different clinical presentation phenotypes of hospital-onset sepsis, 2) Develop a predictive model to forecast ARF risk in these patients, and 3) Assess how...
This Project Grant award of $2,102,163 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to implement an integrative genomic approach to identify genetically-driven pathways of chronic obstructive pulmonary disease (COPD). The primary awardee, Brigham & Women's Hospital, will use existing and generate new GWAS data, along with transcriptomics, proteomics, and newly collected lung/blood metabolomics data from 1,500 subjects, to determine...
This $807,434 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to characterize alternative splicing related to chronic obstructive pulmonary disease (COPD) and cigarette smoke exposure in human airway epithelial cells. The project aims to:
Generate the first genome-wide splicing quantitative trait loci (sQTL) maps for fully differentiated human airway epithelial cells exposed to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $313,632.00 to National Jewish Health in Denver, Colorado to support a 5-year research project. The project aims to determine if fibroblast apoptosis resistance in progressive pulmonary fibrosis is driven by sustained interleukin-6 (IL-6) signaling, and whether targeting the IL-6-BCL-2 axis can be a viable therapeutic approach. The...
This $480,990 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) Cardiovascular Diseases Research program (CFDA 93.837) supports research on the role of aerocytes, a specialized capillary endothelial cell population, in alveolar epithelial regeneration following acute lung injury. The research aims to investigate how aerocyte-derived signaling, particularly the R-spondin3 molecule, guides the regenerative remodeling of alveolar epithelium and establishes a...